HEALTH PROFESSIONAL · SOURCE READING

c-KIT inhibitors

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors

Early data suggest that mucosal or acral melanomas with activating pathogenic variants or amplifications in KIT may be sensitive to a variety of c-KIT inhibitors.[29-31] Phase II and phase III trials are available for patients with unresectable stage III or stage IV melanoma and a KIT pathogenic variant.

Source links and citations

Publication references

Read the original reference and check its publication notices.

PubMed 18421059 · Original source
PubMed 21642685 · Original source

Preserved source evidence · Not medical advice